Home  
  Our Team  
  Patient Info  
  Services  
   
  Pay My Bill  
  Contact Us  

News for Healthier Living

RAS(ON) Inhibitor Daraxonrasib Shows Promising Results in Advanced Pancreatic Cancer Phase 1/2 Study

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in a phase 1/2 first-in-human trial in patients with previously treated, RAS-mutant, metastatic pancreatic cancer, according to a clinical trial led at Dana-Farber Cancer Institute and across the country.

May 7, 2026


May 12 2026

May 11 2026

May 10 2026

May 8 2026

May 7 2026

May 6 2026

May 5 2026

May 4 2026

May 1 2026

April 30 2026

April 29 2026

April 28 2026